Buy, Sell or Hold: Akebia Therapeutics (AKBA-Q)

Home

Daily Stock Opinions and Ratings

Akebia Therapeutics (AKBA-Q)

3.83

-0.14 (3.53%)

as of Jul 15, 2025, 6:45:51 pm Market Open.

1 watching

Nervous markets await Nvidia

RISKY

A total dice roll, a spec stock.

Showing 1 to 1 of 1 entries

Akebia Therapeutics(AKBA-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Akebia Therapeutics is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Akebia Therapeutics(AKBA-Q) Frequently Asked Questions

What is Akebia Therapeutics stock symbol?

Akebia Therapeutics is a American stock, trading under the symbol AKBA-Q on the NASDAQ (AKBA). It is usually referred to as NASDAQ:AKBA or AKBA-Q

Is Akebia Therapeutics a buy or a sell?

In the last year, there was no coverage of Akebia Therapeutics published on Stockchase.

Is Akebia Therapeutics a good investment or a top pick?

Akebia Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Akebia Therapeutics.

Why is Akebia Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Akebia Therapeutics worth watching?

In the last year, there was no coverage of Akebia Therapeutics published on Stockchase.

What is Akebia Therapeutics stock price?

On 2025-07-15, Akebia Therapeutics (AKBA-Q) stock closed at a price of $3.83.

Most Recent Experts

Gordon Reid

GoodReid Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Greg Dean

Cambridge Global Asset Management

Stockchase Insights

5i Research

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.